[go: up one dir, main page]

PE122599A1 - Nuevas formas polimorficas cristalinas de cipamfilina - Google Patents

Nuevas formas polimorficas cristalinas de cipamfilina

Info

Publication number
PE122599A1
PE122599A1 PE1998001002A PE00100298A PE122599A1 PE 122599 A1 PE122599 A1 PE 122599A1 PE 1998001002 A PE1998001002 A PE 1998001002A PE 00100298 A PE00100298 A PE 00100298A PE 122599 A1 PE122599 A1 PE 122599A1
Authority
PE
Peru
Prior art keywords
cypamfiline
new
polymorphic forms
crystalline polymorphic
refers
Prior art date
Application number
PE1998001002A
Other languages
English (en)
Inventor
Drake Eggleston
Ian Robert Lynch
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE122599A1 publication Critical patent/PE122599A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A POLIMORFOS CRISTALINOS (FORMA I, II Y IV) DE 1,3-DICICLOPROPILMETIL-8-AMINOXANTINA (CIPAMFILINA), QUE SE CARACTERIZAN POR SUS PROPIEDADES FISICAS COMO SU PATRON DE DIFRACCION DE RAYOS X, SU ESPECTRO DE ABSORCION INFRARROJO, POR SU ANALISIS CRISTALOGRAFICO POR RAYOS X, A TRAVES DE MONOCRISTALES, SU ESPECTROSCOPIA RAMAN; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE a)DISOLVER 1,3-DICICLOPROPILMETIL-8-AMINOXANTINA EN 1-PROPANOL MEZCLADO CON AGUA; b)ENFRIAR LA DISOLUCION, A 25°C PARA QUE CRISTALICE LA FORMA I POLIMORFICA. LA CIPAMFILINA ES UN INHIBIDOR DE FOSFODIESTERASA (PDE4) Y DEL FACTOR DE NECROSIS TUMORAL (TNF)
PE1998001002A 1997-10-23 1998-10-23 Nuevas formas polimorficas cristalinas de cipamfilina PE122599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6323897P 1997-10-23 1997-10-23

Publications (1)

Publication Number Publication Date
PE122599A1 true PE122599A1 (es) 2000-02-12

Family

ID=22047900

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001002A PE122599A1 (es) 1997-10-23 1998-10-23 Nuevas formas polimorficas cristalinas de cipamfilina

Country Status (28)

Country Link
US (2) US6583283B1 (es)
EP (1) EP1025103A4 (es)
JP (1) JP2001520228A (es)
KR (1) KR20010031246A (es)
CN (1) CN1280579A (es)
AP (1) AP2000001793A0 (es)
AR (1) AR015190A1 (es)
AU (1) AU751561B2 (es)
BG (1) BG104368A (es)
BR (1) BR9814099A (es)
CA (1) CA2306980A1 (es)
CO (1) CO4990930A1 (es)
DZ (1) DZ2629A1 (es)
EA (1) EA003445B1 (es)
HU (1) HUP0100019A3 (es)
ID (1) ID23885A (es)
IL (1) IL135711A0 (es)
MA (1) MA24682A1 (es)
NO (1) NO20002012L (es)
NZ (1) NZ504051A (es)
PE (1) PE122599A1 (es)
PL (1) PL340257A1 (es)
SA (1) SA99191117A (es)
SK (1) SK5642000A3 (es)
TR (1) TR200001109T2 (es)
UY (2) UY25220A1 (es)
WO (1) WO1999020625A1 (es)
ZA (1) ZA989622B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060896A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
PL364135A1 (en) 2001-01-31 2004-12-13 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
CA2436551A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
PE20040538A1 (es) * 2002-05-31 2004-08-30 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v
EP1742627A4 (en) 2004-05-06 2009-08-26 Plexxikon Inc PDE4B HEMMER AND ITS USE
CN101048407A (zh) 2004-09-03 2007-10-03 普莱希科公司 双环杂芳基pde4b抑制剂
EP2082741A1 (en) * 2005-09-20 2009-07-29 Scinopharm Singapore Pte, Ltd. Novel crystal form of irinotecan hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
IL135711A0 (en) 2001-05-20
DZ2629A1 (fr) 2003-03-08
EP1025103A1 (en) 2000-08-09
AU1274499A (en) 1999-05-10
TR200001109T2 (tr) 2000-09-21
PL340257A1 (en) 2001-01-29
BG104368A (en) 2001-02-28
NZ504051A (en) 2003-02-28
AR015190A1 (es) 2001-04-18
CN1280579A (zh) 2001-01-17
AU751561B2 (en) 2002-08-22
EA003445B1 (ru) 2003-06-26
SK5642000A3 (en) 2000-09-12
CO4990930A1 (es) 2000-12-26
CA2306980A1 (en) 1999-04-29
KR20010031246A (ko) 2001-04-16
HUP0100019A3 (en) 2003-01-28
EP1025103A4 (en) 2001-11-14
WO1999020625A1 (en) 1999-04-29
HUP0100019A2 (hu) 2002-01-28
JP2001520228A (ja) 2001-10-30
ZA989622B (en) 1999-04-23
US6583283B1 (en) 2003-06-24
ID23885A (id) 2000-05-25
MA24682A1 (fr) 1999-07-01
NO20002012D0 (no) 2000-04-17
SA99191117A (ar) 2005-12-03
EA200000448A1 (ru) 2000-10-30
UY25380A1 (es) 1999-11-17
AP2000001793A0 (en) 2000-06-30
BR9814099A (pt) 2000-10-10
UY25220A1 (es) 2001-08-27
NO20002012L (no) 2000-04-17
US20020173648A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
PE122599A1 (es) Nuevas formas polimorficas cristalinas de cipamfilina
UY27906A1 (es) Inhibidores de quinasas
BRPI0415760A (pt) derivados de benzimidazolila
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
PE20050700A1 (es) SAL DE ISETIONATO DE 6-ACETIL-8-CICLOPENTIL-5-METIL-2-(5-PIPERAZIN-1-IL-PIRIDIN-2-ILAMINO)-8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA COMO INHIBIDOR SELECTIVO DE CDK4
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
IS7319A (is) Fjölgervingar klópídógrelvetnissúlfats
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
AR064035A1 (es) Polimorfos de la sal succinato de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo y sus metodos de uso
AR026052A1 (es) Derivados de purina
UY26099A1 (es) Procedimiento para preparar formas anhidras e hidratadas de mesilato de n -(3-etinilfenil)-6,7- bis (2- metoxietoxi)-4- quinazolinaminan
MX9307974A (es) Nuevos derivados de acido hidroxiiminoalquilindolcarboxilico, su obtencion y uso.
HN1999000146A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
CR7608A (es) Derivados de ciclotiocarbamativa como moduladores de rp y uso de los mismos para tratamiento de trastornos de la piel
ECSP045330A (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su utilización y procedimiento para su preparación
ECSP077306A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorios
Freeman et al. ULTRAVIOLET WAVELENGTH FACTORS IN SOLAR RADIATION AND SKIN CANCER.
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
IT8621354A0 (it) Rubinetto miscelatore per acqua del tipo monocomando, con mezzi, di regolazione fine della temperatura di mescelazione.
ECSP003590A (es) Compuestos calcioliticos
AR046672A1 (es) Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol
BR0213264A (pt) Produtos cerâmicos, formulações de bateladas de matérias-primas e processo
ATE297926T1 (de) Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
PA8513301A1 (es) Inhibidor del intercambiador de sodio-hidrògeno de tipo 1

Legal Events

Date Code Title Description
FD Application declared void or lapsed